Turn Therapeutics (TTRX) Net Income towards Common Stockholders (2024 - 2026)

Turn Therapeutics' Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at -$1.2 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 215.0% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at -$5.7 million (changed N/A YoY), while the FY2025 annual figure was -$5.8 million, down 229.62% from the prior year.
• Net Income towards Common Stockholders was -$1.2 million for Q1 2026 at Turn Therapeutics, up from -$2.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$323130.0 in Q4 2024 to a low of -$2.2 million in Q4 2025.
• Historically, Net Income towards Common Stockholders has averaged -$1.1 million across 3 years, with a median of -$931453.0 in 2024.
• Biggest YoY gain for Net Income towards Common Stockholders was 186.36% in 2025; the steepest drop was 574.46% in 2025.
• A 3-year view of Net Income towards Common Stockholders shows it stood at -$323130.0 in 2024, then slumped by 574.46% to -$2.2 million in 2025, then soared by 45.1% to -$1.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$1.2 million (Q1 2026), -$2.2 million (Q4 2025), and -$1.9 million (Q3 2025), per Business Quant data.